Navigation Links
Phase 2a Data for MEDI-528 Presented at CHEST 2008
Date:10/29/2008

PLYMOUTH MEETING, Pa., Oct. 29 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today reported that development partner MedImmune, Inc. presented interim Phase 2a data on MEDI-528, its monoclonal antibody (MAb) targeting interleukin-9 (IL-9) in adults with mild, persistent asthma, at The American College of Chest Physicians meeting held October 25-30 in Philadelphia, Pennsylvania.

The presentation, entitled "Multiple Subcutaneous Doses of MEDI-528, A Monoclonal Antibody Against Interleukin-9 in Mild and Moderate Asthmatics," reported the absence of serious, dose-limiting adverse events in the study and concluded that the data demonstrate an acceptable safety profile for multiple subcutaneous doses of MEDI-528.

About IL-9

IL-9 is one of at least 29 naturally occurring interleukins in the human body. Overexpression of IL-9 in animal models has been shown to result in many features of asthma, including increased airway inflammation and hyperreactivity. Blocking the actions of IL-9 has been shown to reduce the airway inflammation and increased airway inflammation and increased airway hyperresponsiveness seen in animal models of asthma. MedImmune is conducting research to evaluate the potential to use MAbs targeting IL-9 to treat or prevent symptomatic, moderate-to-severe, persistent asthma.

About Genaera

Genaera Corporation is developing trodusquemine (MSI-1436) for type 2 diabetes and obesity currently in phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma. For further information, please see our website at http://www.genaera.com.

This announcement contains f
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Ovation further advances development pipeline with new phase III epilepsy study
2. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
3. Mannatech Launches Phase One of New Sales and Training Tools
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Manic phase of bipolar disorder benefits from breast cancer medication
6. ARIZONA METH PROJECT Unveils Arizonas Anti-Meth Youth Pledge and Kicks Off Phase Two of Public Awareness Campaign
7. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
8. Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
9. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
10. MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R)
11. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... Pittsburgh, PA (PRWEB) April 28, 2015 ... by Blair A. Jobe, MD, FACS , has ... replacing esophageal tissue with extracellular matrix (ECM) can help ... lethal form of esophageal cancer. , ECM is a ... for cell attachment and migration and signals that guide ...
(Date:4/28/2015)... 2015 As the Muscular Dystrophy ... services programs, the organization has hired Scientific Program ... MDA from Fidelity Biosciences Research Initiative where, as ... in neurodegenerative diseases such as Alzheimer’s Disease, and ... time at Fidelity, she was a junior faculty ...
(Date:4/28/2015)... 2015 Researchers from four US medical ... a steroid prior to pemetrexed (Alimta) chemotherapy may keep ... Click here to read the full story on ... Raabe College of Pharmacy in Ohio, Stanford Cancer Institute ... Healthcare in Kentucky gave a single dose of dexamethasone ...
(Date:4/28/2015)... 2015 SeniorCare.com has published the ... reality problem Americans have regarding aging and long-term care ... care services as they age, 63% of Americans do ... In the report, Carol Marak of SeniorCare.com interviewed 44 ... Health Care Association and The Scan Foundation. The experts ...
(Date:4/28/2015)... Enrollment in programs designed to coordinate ... in April, according to the editors of Atlantic ... Eligibles Database , an online subscription resource that ... community. This is a 14% increase since the ... January, but only covers about a quarter of ...
Breaking Medicine News(10 mins):Health News:Allegheny Health Network Launches First U.S. Clinical Trial of Extracellular Matrix as Replacement for Pre-Cancerous Tissue 2Health News:Allegheny Health Network Launches First U.S. Clinical Trial of Extracellular Matrix as Replacement for Pre-Cancerous Tissue 3Health News:MDA Adds Neurological Disease Expert to Research Team 2Health News:MDA Adds Neurological Disease Expert to Research Team 3Health News:Study Finds New Regimen May Ward Off Skin Rash from Common Mesothelioma Drug, According to Surviving Mesothelioma 2Health News:SeniorCare.com Report: America Has a Major Misconception on Aging 2Health News:Enrollment in Duals Programs Increases 14%, New AIS Database Finds 2
... complicated. Thomas Jefferson University biochemistry researchers have shown ... insect molting hormone doesn,t activate and repress genes as once ... out-competed by a heme-binding receptor to repress the same genes ... For the last 20 years, the nuclear receptor known ...
... U.S. Food and Drug Administration and the National Institutes ... of tobacco users to monitor and assess the behavioral ... The initiative, called the Tobacco Control Act National Longitudinal ... collaboration on tobacco regulatory research since Congress granted FDA ...
... and diagnosis of open angle glaucoma important so that treatment ... developing to prevent or avoid further vision loss. Writing in ... Engineering and Informatics , researchers in the US have analyzed ... so that patients can be screened at an earlier stage ...
... , THURSDAY, Oct. 6 (HealthDay News) -- ,Anemia ... have different types of surgery, not just heart operations, a ... anemia have worse outcomes after heart surgery, but anemia,s impact ... deficient in red blood cells. For the new ...
... had been given DES, the first synthetic form of estrogen, ... in the womb (in utero) is associated with many reproductive ... conditions. The results of this analysis, conducted by researchers at ... of Health, and collaborators across the country, were published Oct. ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, Oct. ... forms of multiple sclerosis appears to reduce relapse rates and ... 3 trial. The experimental drug, teriflunomide, is one of ... and may, if approved, be a good choice for many ...
Cached Medicine News:Health News:Nuclear receptors battle it out during metamorphosis in new fruit fly model 2Health News:FDA and NIH announce joint study on tobacco use and risk perceptions 2Health News:Detecting glaucoma before it blinds 2Health News:Anemia Could Add to Surgical Risks 2Health News:Women exposed to diethylstilbestrol in the womb face increased cancer risk 2Health News:Women exposed to diethylstilbestrol in the womb face increased cancer risk 3Health News:Experimental MS Drug Shows Promise 2Health News:Experimental MS Drug Shows Promise 3
(Date:4/28/2015)... Exagen Diagnostics, Inc., a commercial-stage diagnostics ... for the accurate diagnosis and monitoring of patients ... its Avise SLE+ Connective Tissue 2.0 diagnostic has ... and that adoption continues to grow. The Avise ... Disease (CTD), including, but not limited to, Systemic ...
(Date:4/28/2015)... 28, 2015 Semler Scientific, Inc. (Nasdaq: ... develops, manufactures and markets patented products that assist healthcare ... announced that it has received an order from another ... country who offer Medicare Advantage programs. This brings the ... plans who are now customers of Semler. ...
(Date:4/28/2015)... 2015   HX360 today announced that ... inaugural HX360 Innovation Challenge competition, recognizing ... experience in hospital and health system settings.  The ... of eighty-three entries, with the four finalists presenting ... the HX360 Innovation Challenge program at HIMSS15 last ...
Breaking Medicine Technology:Exagen Sees Growing Adoption of Avise Diagnostic for Connective Tissue Disease with New Milestone 2Semler Adds Top Insurance Plan to Customer List 2Semler Adds Top Insurance Plan to Customer List 3Ginger.io And WiserCare Named Winners Of The HX360 Innovation Challenge 2Ginger.io And WiserCare Named Winners Of The HX360 Innovation Challenge 3
...  BSI,s Healthcare Solutions Group is hosting a free webinar on ... is scheduled for January 26 and is intended to address ... how to be prepared. (Logo: http://photos.prnewswire.com/prnh/20110405/NE77664LOGO ... to help the audience understand the current status and upcoming ...
... (Nasdaq: CDXS ) today announced that the Company,s ... his decision to resign as Chief Financial Officer in order ... Board of Directors will conduct an immediate search for a ... contributions to Codexis," said Alan Shaw, Ph. D, President and ...
Cached Medicine Technology:FREE Webinar: Revision of the In Vitro Diagnostic Directive 2
... Introducing the new large ... new handpieces function as both ... the ultimate in flexibility. Its ... always wanted with the security ...
... 7600 Oscillating Saw offers unparalleled ... thanks to its 14.4V NiMH ... head may be rotated into ... any plane and will accept ...
... Breakthrough in Battery Powered Orthopedic Systems., ... new addition to the Hall® Surgical line ... System is the first and only software ... market. It is a full-function orthopedic power ...
... Introducing the new large ... Our new handpieces function ... electric instruments, offering the ... the versatility the industry ...
Medicine Products: